KLK3 and prostate cancer: In 1 of the 7 RCTs,18 a hypothesis-generating postrandomization analysis of OS stratified by PSA level was performed and yielded a hazard ratio (HR) of 0.33 among men with high-grade prostate cancer with low PSA levels when docetaxel was added to testosterone suppression for 6 months and primary radiotherapy.